Remus Pharmaceuticals Limited is a rapidly growing pharmaceutical company established in 2015, specializing in the marketing and distribution of niche off-patent formulations.

The company operates an asset-light model, boasting a portfolio of over 800 approved products across major therapeutic segments such as oncology and cardiology, and serves more than 40 countries.

In 2024, Remus expanded into the U.S. market through the acquisition of Espee Global Holdings LLC, solidifying its presence in the specialty and biosimilar drugs sector.

The company's strategy involves robust partnerships with multinational pharmaceutical firms, allowing for expanded market reach through Channel Partners for governmental and institutional tenders.

Investments in R&D focus on expanding their product portfolio, targeting new territories while aiming to achieve first-mover advantages in off-patent drugs.